miRNA-1 promotes acute myeloid leukemia cell pathogenesis through metabolic regulation

Ghazaryan, Arevik; Wallace, Jared; Tang, William W.; Barba, Cindy; Lee, Soh-Hyun; Bauer, Kaylyn M.; Nelson, Morgan C.; Kim, Carissa N.; Stubben, Chris; Voth, Warren P.; Rao, Dinesh S.; O’Connell, Ryan M.

doi:10.3389/fgene.2023.1192799

Cited by 4 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many reports presented the association between miRNA expression and specific chromosomal abnormalities [26,27] or mutations in AML [28][29][30]. On the other hand, miRNAs were also associated with prognosis, disease progression, or proliferation [31][32][33][34]. Based on these findings, miRNAs are now regarded as important biomarkers that might predict the response to treatment, the risk of progression, or the rate of complete remission (CR) and overall survival (OS) in both solid cancers of hematological malignancies [35][36][37][38].…”

Section: Mirnas and Cancermentioning

confidence: 99%

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization

Jimbu,

Mesaros,

Joldes

et al. 2024

Biomedicines

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short, non-coding ribonucleic acids (RNAs) associated with gene expression regulation. Since the discovery of the first miRNA in 1993, thousands of miRNAs have been studied and they have been associated not only with physiological processes, but also with various diseases such as cancer and inflammatory conditions. MiRNAs have proven to be not only significant biomarkers but also an interesting therapeutic target in various diseases, including cancer. In acute myeloid leukemia (AML), miRNAs have been regarded as a welcome addition to the limited therapeutic armamentarium, and there is a vast amount of data on miRNAs and their dysregulation. Macrophages are innate immune cells, present in various tissues involved in both tissue repair and phagocytosis. Based on their polarization, macrophages can be classified into two groups: M1 macrophages with pro-inflammatory functions and M2 macrophages with an anti-inflammatory action. In cancer, M2 macrophages are associated with tumor evasion, metastasis, and a poor outcome. Several miRNAs have been associated with a poor prognosis in AML and with either the M1 or M2 macrophage phenotype. In the present paper, we review miRNAs with a reported negative prognostic significance in cancer with a focus on AML and analyze their potential impact on macrophage polarization.

show abstract

Section: Mirnas and Cancermentioning

confidence: 99%

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization

Jimbu,

Mesaros,

Joldes

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

The effect of miR-223-3p on endothelial cells in coronary artery disease

Zhao,

Zang,

Gui

et al. 2023

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

miRNA Profiles in Patients with Hematological Malignancy at Different Stages of the Disease: A Preliminary Study

Hashem,

Alkhalaileh,

Abushukair

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The dysregulation of miRNA expression has been shown to impact cellular physiology and tumorigenesis. Studies have reported several miRNA regulatory elements and pathways that play a significant role in the diagnosis, prognosis, and treatment of hematological malignancies. This is the first study to test the differential expression of miRNAs at crucial stages of the disease, specifically newly diagnosed, resistant to treatment, and remission. Circulating miRNAs extracted from the blood samples of 18 patients diagnosed with leukemia or lymphoma at different stages and 2 healthy controls were quantified by qPCR using a panel of 96 tumorigenic miRNAs. An enrichment analysis was performed to understand the mechanisms through which differential miRNA expression affects cellular and molecular functions. Significant upregulation of hsa-miR-1, hsa-miR-20a-5p, hsa-miR-23a-3p, hsa-miR-92b3p, and hsa-miR-196a-5p was detected among the different stages of leukemia and lymphoma. mir-1 and mir-196a-5p were upregulated in the remission stage of leukemia, while mir-20a-5p, mir-23a-3p, and mir-92b-3p were upregulated during the resistant stage of lymphoma. The enrichment analysis revealed these miRNAs’ involvement in the RAS signaling pathway, TGF-β signaling, and apoptotic pathways, among others. This study highlights new biomarkers that could be used as potential targets for disease diagnosis, prognosis, and treatment, therefore enhancing personalized treatments and survival outcomes for patients.

show abstract

miRNA-1 promotes acute myeloid leukemia cell pathogenesis through metabolic regulation

Cited by 4 publications

References 52 publications

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization

The effect of miR-223-3p on endothelial cells in coronary artery disease

miRNA Profiles in Patients with Hematological Malignancy at Different Stages of the Disease: A Preliminary Study

Contact Info

Product

Resources

About